Corcept Therapeutics Incorporated Stock Price and Value Analysis

Should you buy Corcept Therapeutics Incorporated stock? (NasdaqCM:CORT). Let's see how it does in our automated value investing analysis system.

CORT Free Cash Flow Trend

Free Cash Flow trendline for CORT
Free Cash Flow trendline for Corcept Therapeutics Incorporated

Hmm, we can't give any reliable projection for Corcept Therapeutics Incorporated's growth rate. The company either has too few years of historical data for us to examine, or it's in the habit of losing money.

None of this means it's a bad stock. Maybe it's new and growing quickly, or maybe it's turning things around. We can't say anything sensible about it, so we won't say it's obviously undervalued right now. Proceed at your own risk!

  • This company is solid.
  • This stock looks overpriced.
  • This company has wild ups and downs.
  • This company is not making money.
  • This company pays no dividend.

Inside the CORT Numbers

CORT Price
(Corcept Therapeutics Incorporated stock price per share)
[?] PE Ratio versus Sector 2% lower than other Healthcare stocks
[?] PE Ratio versus Industry 65% lower than other Biotechnology stocks
[?] Cash Yield 0.16%
[?] Free Cash Flow Jitter 198%

Is Corcept Therapeutics Incorporated Stock on Sale?

Based on our analysis, we believe that you should not buy Corcept Therapeutics Incorporated right now. It might be a good stock to own—we just can't prove it with value analysis right now. Proceed with caution.

Should You Buy CORT Stock?

Does Corcept Therapeutics Incorporated have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.